The main therapies for cancer include extensive tumor resection, radiation therapy and chemotherapy. However, the elucidation of molecules related to the development, proliferation, survival and immune escape in cancer cells has improved through recent advances in molecular biology and immunology. Based on these findings, a series of cancer immune therapies has been developed and clinical trials have led to the approval of several drugs. In this article, I summarize the immune checkpoint and immune checkpoint inhibitors that have recently been worthy of note.
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